Hugo Fry – Managing Director, Sanofi UK
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
Address: Sanofi-Aventis, One Onslow Street, Guildford, Surrey GU1 4YS, United Kingdom
Tel: +44 (0)1483 505 515
Web: http://www.sanofi.co.uk/l/gb/en/index.jsp
Sanofi UK, an affiliate of the global pharmaceutical company Sanofi, is a dynamic, rapidly growing organisation that is working to meet the needs of healthcare professionals and their patients.
Sanofi in the UK provides medicines to treat patients with illnesses in several therapeutic areas: cardiovascular, thrombosis, central nervous system, oncology, metabolic disorders and internal medicine
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
See our Cookie Privacy Policy Here